In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

The real drug development delay? Bad communication.

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Psychedelic therapy developer Definium Therapeutics convinced a federal judge in Delaware on Wednesday to dismiss a lawsuit ...

A French drugmaker just bet up to $1.75 billion on a cancer drug that's only been tested on 19 patients — why?

The industry contributes $50 billion to the state GDP, and employs 130,000 people across research and manufacturing.

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.